Last reviewed · How we verify
BEACOPP regimen
BEACOPP is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.
BEACOPP is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms. Used for Hodgkin lymphoma, advanced stages (IIB-IV), Hodgkin lymphoma, high-risk disease.
At a glance
| Generic name | BEACOPP regimen |
|---|---|
| Sponsor | SWOG Cancer Research Network |
| Drug class | Polychemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BEACOPP is an intensive polychemotherapy regimen designed for Hodgkin lymphoma treatment. It works through multiple mechanisms: alkylating agents (cyclophosphamide, procarbazine) cross-link DNA; topoisomerase inhibitors (etoposide) prevent DNA unwinding; anthracyclines (doxorubicin) intercalate DNA and generate reactive oxygen species; vinca alkaloids (vincristine) disrupt microtubule formation; and bleomycin causes DNA strand breaks. The combination targets rapidly dividing malignant cells while prednisone provides immunosuppression and anti-inflammatory effects.
Approved indications
- Hodgkin lymphoma, advanced stages (IIB-IV)
- Hodgkin lymphoma, high-risk disease
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Infection
- Cardiotoxicity (doxorubicin-related)
- Pulmonary toxicity (bleomycin-related)
- Infertility/gonadal dysfunction
- Secondary malignancies
Key clinical trials
- Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL (PHASE2)
- FIL Study on ABVD DD-DI as Upfront Therapy in HL. (PHASE3)
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma (PHASE3)
- HD21 for Advanced Stages (PHASE3)
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (PHASE3)
- Prognostic Significance of ctDNA in HL
- Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEACOPP regimen CI brief — competitive landscape report
- BEACOPP regimen updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI